Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A A Modi

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Oral Diseases|January 5, 2008
Hepatitis C: a clinical reviewA A Modi, T J Liang
Alimentary Pharmacology & Therapeutics|March 24, 2018
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvirA A Modi, H E Nazario, G R Gonzales, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine responseY Rotman, B B Borg, A Soza, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Oral Diseases|January 5, 2008
Hepatitis C: a clinical reviewA A Modi, T J Liang
Alimentary Pharmacology & Therapeutics|March 24, 2018
Safety and efficacy of ledipasvir/sofosbuvir with or without ribavirin in hepatitis C genotype 1 patients including those with decompensated cirrhosis who failed prior treatment with simeprevir/sofosbuvirA A Modi, H E Nazario, G R Gonzales, et al.
Alimentary Pharmacology & Therapeutics|February 19, 2010
Low- and standard-dose peginterferon alfa-2a for chronic hepatitis C, genotype 2 or 3: efficacy, tolerability, viral kinetics and cytokine responseY Rotman, B B Borg, A Soza, et al.
Pageof 1